Drugs / A52-Mel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06622434 | Nov 2024 → Mar 2028 expected | glioblastoma | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A52-Mel | “A52-Mel: a TERT peptidic epitope adsorbed on synthetic melanin” NCT06622434 ↗ |
| Route | Subcutaneous | “Patients will receive subcutaneous injections in the shoulders of both A49 and A52 at one of 3 pre-specified dose levels of peptides (50-100-250µg) + 1mg of Litenimod (fixed dose).” NCT06622434 ↗ |
| Target | TERT | “A52-Mel: a TERT peptidic epitope adsorbed on synthetic melanin” NCT06622434 ↗ |